EVLO (Evelo Biosciences) Return-on-Tangible-Asset: -238.65% (As of Sep. 2023)


What is Evelo Biosciences Return-on-Tangible-Asset?

Evelo Biosciences EVLO Return-on-Tangible-Asset is -238.65% as of Sep. 2023.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Evelo Biosciences's annualized Net Income for the quarter that ended in Sep. 2023 was $-49.46 Mil. Evelo Biosciences's average total tangible assets for the quarter that ended in Sep. 2023 was $20.72 Mil. Therefore, Evelo Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -238.65%.

The historical rank and industry rank for Evelo Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

EVLO's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -35.77
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Evelo Biosciences  (OTCPK:EVLO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Evelo Biosciences Return-on-Tangible-Asset Related Terms


Evelo Biosciences Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Return-on-Tangible-Asset Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial -55.92 -68.16 -103.18 -136.88 -150.38

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.34 -124.90 -190.51 -268.88 -238.65

EVLO vs IMNN, EDSA, TMBR: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Evelo Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Return-on-Tangible-Asset falls into.



Evelo Biosciences Return-on-Tangible-Asset Calculation

Evelo Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-114.527/( (87.871+64.441)/ 2 )
=-114.527/76.156
=-150.38 %

Evelo Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-49.456/( (20.819+20.627)/ 2 )
=-49.456/20.723
=-238.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data.

What does a Return-on-Tangible-Asset of -238.65% mean?
Evelo Biosciences (EVLO) has a Return-on-Tangible-Asset of -238.65% as of Sep. 2023. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Return-on-Tangible-Asset too high?
Evelo Biosciences' current Return-on-Tangible-Asset is -238.65%.
How does Evelo Biosciences' Return-on-Tangible-Asset compare to IMNN and EDSA?
Evelo Biosciences' Return-on-Tangible-Asset of -238.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Return-on-Tangible-Asset is -238.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Return-on-Tangible-Asset of -238.65%. The current Return-on-Tangible-Asset is -238.65%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Return-on-Tangible-Asset is -238.65% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.